Jian Hu

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Survival Rates After Lobectomy, Segmentectomy, and Wedge Resection for Non-Small Cell Lung Cancer

Jinglin Cao, Ping Yuan, Yiqing Wang et al. · The Annals of Thoracic Surgery · 2018 · 203 citations · Full text

Surgical Oncology, Survival Rates, Medicine +9

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He, Chunxia Su, Wenhua Liang et al. · The Lancet Respiratory Medicine · 2021 · 178 citations

Medicine, Immunology, Pathology +8

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

Nai‐Kong V. Cheung, Hong-Fen Guo, Jian Hu et al. · OncoImmunology · 2012 · 147 citations · Full text

Neuroblastoma Xenografts, Immunology, Immunologic Mechanism +18

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

Charlotte E. Ariyan, Mary Sue Brady, Robert H. Siegelbaum et al. · Cancer Immunology Research · 2018 · 118 citations